A single infusion of anti-CD19 chimeric antigen receptor (CAR) T-cell therapy brexucabtagene autoleucel (Tecartus, Kite) showed promise in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL) during the phase 1/2 ZUMA-3 trial.
“The efficacy, rapid manufacturing and manageable safety profile support the promising role of KTE-X19 [brexucabtagene autoleucel] to provide a long-term clinical benefit in adult patients with relapsed/refractory B-ALL,” said investigator